StockData

Adagene vs Adlai Nortye

ADAG and ANL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ADAG and ANL compare

Adagene keeps more of each dollar of sales as profit, with a net margin of −230% compared with −711% at Adlai Nortye.

Adagene scores higher on the StockData Score (5 against 0 for Adlai Nortye), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricADAGANL
Size and price
Share price$1.60$10.03
Change, 1 year−11.1%564%
Change, 5 years−81.6%–
Beta (5Y)0.613.83
Employees128–
StockData Score
Total score5 (better)0
Valuation score00
Growth score1 (better)0
Performance score2 (better)0
Health score2 (better)0
Dividend score00
Growth
Revenue growth (TTM)7333%–
Revenue growth, 5Y average61.4%–
Profitability
Operating margin−279% (better)−714%
Net margin−230% (better)−711%
FCF margin−204% (better)−673%
Return on equity−27.7%–
Financial health
Debt / equity0.06–
Interest coverage−46.3×−23.3× (better)
Current ratio5.02 (better)0.65
Piotroski F-score4 (better)1
Ownership
Held by institutions32.5%22.1%
Held by insiders16.8%14.7%
Insider net buying, 12 months$162K (better)−$411K

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.